What is it?
What is Cardarine?
1GW501516, also called GW1516, Cardarine or Endurobol, is a synthetic small molecule that activates PPAR-delta, a receptor involved in lipid metabolism. Its mechanism differs from selective androgen receptor modulators (SARMs), despite appearing beside them in online catalogs.
Names, aliases and forms
Potential effects and evidence map
Small and short human trials report changes in lipid biomarkers. Those findings are indirect for memory, focus, fat loss or endurance, and do not establish long-term consumer safety. The overall grade applies to marketed nootropic and performance uses, not to whether lipid pharmacology was observed.
Human lipid trials do not establish an endurance or exercise-performance benefit.
The cited human research does not demonstrate a mental-energy or alertness benefit.
Memory and learning benefits are unestablished by the available human lipid studies.
Typical dosages and timing
Adults with low HDL received one of these doses or placebo in the published study. These are historical investigational exposures, not a supplement dose recommendation; no validated safe consumer regimen follows from this trial.
Timing & effect horizon
The featured study window describes repeated dosing in a lipid trial. It does not show when a cognitive or endurance effect starts, how long one dose acts, or an appropriate cycle. Hair-detection research likewise cannot supply an effect-duration or safe washout value.
Safety, side effects and risk profile
Interactions and cautions
The short lipid-study record does not define safe combinations with medicines, SARMs or other performance products. Lack of established interaction data is not evidence that combining them is safe; specific CYP or organ-interaction claims are not supported here.
Legal and regulatory status
FDA's 12 December 2025 letter named a seller's Cardarine GW501516 product among unapproved new drugs offered in U.S. commerce. The finding concerns those marketed products and their intended use; it is not a worldwide possession rule. The letter's general SARM toxicity claims should not be assigned to Cardarine, which has different pharmacology.
Health Canada's 2020 advisory identifies Cardarine as unauthorized in Canada for any use and warns of serious health risks. This describes the Canadian advisory, not an international rule; national sale, import and possession provisions differ.
How it compares
A 12-week placebo-controlled trial in 268 adults with low HDL measured lipids and apolipoproteins. It reported biomarker changes, including an HDL increase of up to 16.9% at the highest dose. That is not a demonstrated improvement in memory, running performance, body-fat loss or cardiovascular events.
Practical buying and quality notes
- For a label stating 60 capsules at 10 mg each, the declared pack total is 600 mg. Per-capsule and per-pack prices answer different questions; compare matching quantities and strengths. This is label arithmetic, not verification of contents, consumer safety or an endorsement. A research-use disclaimer does not establish approval for human use. An offer row's labeled amount may represent a pack total rather than each capsule. Verify the amount basis on the merchant page; a pack total is not a single-dose amount.4
FAQ
Do human studies support Cardarine as a nootropic?
6The studies cited here examined lipid metabolism rather than memory or attention. Their results do not establish a cognitive benefit.
Is Cardarine a SARM?
1Its target is PPAR-delta, not the androgen receptor. Shared retail categories do not make these compounds pharmacologically interchangeable.
Does short-term human tolerability establish safety?
10The TGA assessment reports no significant adverse effects in the short human studies it reviewed. That observation does not answer the animal cancer concern or establish long-term human safety.
Does research-use-only labeling mean safe for people?
4No. Research labeling does not establish safety, approval or permission for human use. FDA evaluated the named products by their intended use, including website claims, despite such disclaimers.
References
- PubChem. Compound Summary for CID 9803963, GW501516.
- World Anti-Doping Agency. WADA issues alert on GW501516.
- World Anti-Doping Agency. The 2026 Prohibited List.
- U.S. Food and Drug Administration. Dynamic Health Group dba SARMS AMERICA - Warning Letter 719257. December 12, 2025.
- Sprecher DL et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol. 2007;27(2):359-365.
- Ooi EMM et al. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J Clin Endocrinol Metab. 2011;96(10):E1568-E1576.
- Olson EJ et al. Lipid effects of peroxisome proliferator-activated receptor-delta agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb Vasc Biol. 2012;32(9):2289-2294.
- Testing for GW501516 (cardarine) in human hair using LC/MS-MS and confirmation by LC/HRMS. Drug Test Anal. 2020.
- Health Canada. Unauthorized products may pose serious health risks (February 10, 2020 to March 13, 2020).
- Therapeutic Goods Administration. Scheduling delegates' interim decisions and invitation for further comment: ACCS/ACMS, November 2017. Published 5 February 2018; Cardarine assessment, pages 19-30.